Background
Methods
Patient Population
No. of patients (%) | ||||
---|---|---|---|---|
MMD | Controls | P value | ||
Variables | n = 20 | n = 12 | ||
Age | Mean ± SD, years | 20.5 ± 17.4 | 61.2 ± 9.1 | <0.01 |
Sex, n (%) | ||||
Male | 11 (55.0) | 3 (25.0) | 0.1 | |
Female | 9 (45.0) | 9 (75.0) | ||
Type of onset, n (%) | NA | |||
TIA | 12 (60.0) | |||
Infarction | 4 (20.0) | 2 (16.7) | ||
Hemorrhage | 1 (5.0) | |||
Asymptomatic | 2 (10.0) | 7 (58.3) | ||
Others | 1 (5.0) | 3 (25.0) | ||
Associated disease, n (%) | NA | |||
None | 18 (90.0) | |||
Down syndrome | 2 (10.0) | |||
Cerebral aneurysm | 9 (75.0) | |||
Others | 3 (25.0) | |||
Suzuki's angiographycal stage (1-6) | Mean ± SD | 3.05 ± 0.9 | NA |
Sample Collection
Sample preparation and analysis
CSF preparation
ProteinChip array pretreatment
ProteinChip array preparation
SELDI-TOF-MS and data acquisition
Mass spectral processing
Peak detection of SELDI protein profiles
Data analysis for single biomarker candidate protein identification
Data mining using classification and regression trees (CART)
Peak reproducibility
Results
Peak reproducibility
SELDI-TOS-MS protein profiling and data analysis
SELDI-TOF-MS analysis for CSF samples
Univariate analysis using EDM data for identification of single biomarker candidate proteins
P-value* | m/z | pH of binding/washing buffer | ROC AUC | Level in MMD |
---|---|---|---|---|
1.60E-04 | 4746.76 | pH 9 | 0.9000 | up |
5.32E-04 | 4566.71 | pH 5 | 0.8583 | down |
6.14E-04 | 4473.46 a
| pH 5 | 0.8750 | up |
1.08E-03 | 4157.65 | pH 9 | 0.8250 | up |
1.41E-03 | 4589.34 b
| pH 9 | 0.8250 | up |
1.41E-03 | 50989.55 | pH 9 | 0.8417 | down |
1.41E-03 | 4588.73 b
| pH 5 | 0.8250 | up |
3.09E-03 | 4588.87 b
| pH 7 | 0.8000 | up |
3.09E-03 | 6941.48 d
| pH 9 | 0.8083 | down |
3.51E-03 | 6942.96 d
| pH 7 | 0.8167 | down |
7.24E-03 | 9656.51 | pH 5 | 0.8000 | up |
7.24E-03 | 13754.72 | pH 5 | 0.7750 | up |
8.12E-03 | 4809.94 c
| pH 5 | 0.7667 | down |
9.11E-03 | 2406.55 | pH 5 | 0.7667 | down |
9.11E-03 | 13882.19 e
| pH 9 | 0.7583 | down |
1.02E-02 | 9728.65 | pH 5 | 0.7750 | up |
1.14E-02 | 6228.21 | pH 5 | 0.7333 | down |
1.27E-02 | 13877.49 e
| pH 7 | 0.7917 | down |
1.42E-02 | 21299.65 | pH 5 | 0.7583 | down |
1.58E-02 | 5781.11 | pH 5 | 0.7500 | up |
1.76E-02 | 14060.91 | pH 9 | 0.7417 | down |
1.76E-02 | 4695.40 | pH 5 | 0.7417 | down |
1.95E-02 | 6240.88 | pH 9 | 0.7500 | up |
2.16E-02 | 28095.59 | pH 9 | 0.7583 | down |
2.40E-02 | 4475.1 a
| pH 7 | 0.7500 | up |
2.40E-02 | 7250.89 | pH 7 | 0.7250 | up |
2.40E-02 | 3516.49 | pH 9 | 0.7250 | up |
2.93E-02 | 6888.58 | pH 5 | 0.7250 | up |
3.23E-02 | 3681.83 | pH 9 | 0.7250 | up |
3.56E-02 | 1041.03 | pH 9 | 0.7000 | up |
3.91E-02 | 7146.84 | pH 5 | 0.7333 | down |
4.30E-02 | 4811.33 c
| pH 9 | 0.7000 | up |
4.71E-02 | 1061.94 | pH 9 | 0.7250 | up |
4.71E-02 | 34344.75 | pH 5 | 0.7083 | down |
Data mining using CART analysis
Discussion
Purpose of this study
Study design
Evaluation of the results in this study
Definite diagnostic tool for discrimination of patients with MMD and control patients
Comparison analysis using over-expressed/down-regulated proteins in the CSF of patients with MMD
Theoretical MW (Da) | Inferred candidate protein (peptide) |
---|---|
4449.89 | Oxyntomodulin (P01275) |
4451.26 | Urocortin-2 (Q96RP3) |
4461.22 | Beta-defensin 133 (Q30KQ1) |
4493.32 | Antibacterial protein LL-37 (P49913) |
4585.34 | Liver-expressed antimicrobial peptide 2 (Q969E1) |
4586.6 | Proenkephalin-A (143-183) (P01210) |